Pharmaceutical Investing DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma
Pharmaceutical Investing DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
Pharmaceutical Investing DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
Pharmaceutical Investing DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer
Pharmaceutical Investing DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
Pharmaceutical Investing CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead
Pharmaceutical Investing DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market
Pharmaceutical Investing DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083
Pharmaceutical Investing DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
Pharmaceutical Investing DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
Pharmaceutical Investing DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
Pharmaceutical Investing DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Pharmaceutical Investing DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
CHARBONE Hydrogen and ABB Sign Agreement to Advance North American Green Hydrogen Production Facilities
